Advertisement

Tumor Biology

, Volume 37, Issue 1, pp 583–590 | Cite as

Bioinformatic analyses revealed underlying biological functions correlated with oxaliplatin responsiveness

  • Sukhontip Klahan
  • Chi-Cheng Huang
  • Shu-Chen Chien
  • Mei-Shin Wu
  • Henry Sung-Ching Wong
  • Chien-Yu Huang
  • Wei-Chiao Chang
  • Po-Li Wei
Original Article
  • 327 Downloads

Abstract

Colorectal cancer is one of the most common cancers worldwide. Surgery is usually the primary treatment for colon cancers that have not spread to distant sites. However, chemotherapy may be considered after surgery to eliminate remaining cancer cells or in case the cancer has a high risk of recurrence. Oxaliplatin is often used in combination regimens such as FOLFOX, CapeOX, and FOLFOXIRI because of the cost-effectiveness of adjuvant treatment for patients and also the good tolerability profile. However, some patients show resistance to oxaliplatin which causes poor treatment outcomes. Most colon cancer studies focused on treatments and patient survival. Some studies focused on genetic associations of specific genes. However, pathway and network analyses of oxaliplatin resistance in colon cancer cells using gene expression patterns are still lacking. We performed a microarray analysis and found that endothelin-1 (EDN1), dishevelled segment polarity protein (DV1), toll-like receptor 5(TLR5), mitogen-activated protein kinase 3 (MAP2K3), phosphatidylinositol-4,5-bisphosphate 3-kinase, and catalytic subunit beta (PIK3CB) were closely related to responsiveness to oxaliplatin treatment. Furthermore, we found that the signal transduction, melanogenesis, and toll-like receptor signaling pathways might be involved in oxaliplatin-resistant colon cancer. These genes and pathways might be potential targets for improving oxaliplatin treatment in colon cancer patients.

Keywords

Bioinformatic analysis Colon cancer Oxaliplatin Network and pathway analysis 

Notes

Acknowledgments

This work was supported by Grants from The National Science Council (NSC101-2320-B-038-029-MY3) and the National Taipei University of Technology and Taipei Medical University Join Research (USTP-NTUT-TMU-104-12)

Conflicts of interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Supplementary material

13277_2015_3807_MOESM1_ESM.doc (60 kb)
ESM 1 (DOC 93 kb)
13277_2015_3807_MOESM2_ESM.doc (30 kb)
ESM 2 (DOC 61 kb)

References

  1. 1.
    Binefa G et al. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20(22):6786–808.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002;38(7):1023–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Gunderson LL et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28(2):264–71.CrossRefPubMedGoogle Scholar
  5. 5.
    O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet, 1995. 345(8955): p. 939–44.Google Scholar
  7. 7.
    Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–704.CrossRefPubMedGoogle Scholar
  8. 8.
    Porschen R et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol. 2001;19(6):1787–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Andre T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Haller DG et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Aballea S et al. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer. 2007;43(11):1687–93.CrossRefPubMedGoogle Scholar
  12. 12.
    Attard CL et al. Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada. Curr Oncol. 2010;17(1):17–24.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Shiroiwa T et al. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial. Value Health. 2012;15(2):255–60.CrossRefPubMedGoogle Scholar
  14. 14.
    Lairson DR et al. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer. Pharmacoeconomics. 2014;32(10):1005–13.CrossRefPubMedGoogle Scholar
  15. 15.
    Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf. 2003;2(6):597–607.CrossRefPubMedGoogle Scholar
  16. 16.
    de Gramont A et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.CrossRefPubMedGoogle Scholar
  17. 17.
    Di Francia R et al. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anti-cancer Drugs. 2013;24(10):1069–78.CrossRefPubMedGoogle Scholar
  18. 18.
    Lecomte T et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res. 2006;12(10):3050–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Gamelin L et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res. 2007;13(21):6359–68.CrossRefPubMedGoogle Scholar
  20. 20.
    Ramanathan RK et al. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol. 2010;21(4):754–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 2005;31(2):90–105.CrossRefPubMedGoogle Scholar
  22. 22.
    Brookes AJ. The essence of SNPs. Gene. 1999;234(2):177–86.CrossRefPubMedGoogle Scholar
  23. 23.
    Wei JC et al. Association study of polymorphisms rs4552569 and rs17095830 and the risk of ankylosing spondylitis in a Taiwanese population. PLoS One. 2013;8(1), e52801.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Yen JH et al. A polymorphism of ORAI1 rs7135617, is associated with susceptibility to rheumatoid arthritis. Mediat Inflamm. 2014;2014:834831.CrossRefGoogle Scholar
  25. 25.
    Chang WC. Pharmacogenomics in personalized medicine and drug metabolism. Biomed Res Int. 2014;2014:897963.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Chang HW et al. The importance of integrating SNP and cheminformatics resources to pharmacogenomics. Curr Drug Metab. 2012;13(7):991–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Ruzzo A et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007;25(10):1247–54.CrossRefPubMedGoogle Scholar
  28. 28.
    Park DJ et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001;61(24):8654–8.PubMedGoogle Scholar
  29. 29.
    Stoehlmacher J et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer. 2004;91(2):344–54.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Braun MS et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008;26(16):2690–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Monzo M et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology. 2007;72(5–6):364–70.PubMedGoogle Scholar
  32. 32.
    Viguier J et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005;11(17):6212–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Martinez-Balibrea E et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer. 2008;44(9):1229–37.CrossRefPubMedGoogle Scholar
  34. 34.
    Puyo S et al. Gene expression signature predicting high-grade prostate cancer responses to oxaliplatin. Mol Pharmacol. 2012;82(6):1205–16.CrossRefPubMedGoogle Scholar
  35. 35.
    Aubert J et al. Determination of the differentially expressed genes in microarray experiments using local FDR. BMC Bioinf. 2004;5:125.CrossRefGoogle Scholar
  36. 36.
    de Gramont A et al. From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol. 2011;38(4):521–32.CrossRefPubMedGoogle Scholar
  37. 37.
    Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134(5):1296–310.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Lee ME et al. Functional analysis of the endothelin-1 gene promoter. Evidence for an endothelial cell-specific cis-acting sequence. J Biol Chem. 1990;265(18):10446–50.PubMedGoogle Scholar
  39. 39.
    Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev. 1993;73(2):375–411.PubMedGoogle Scholar
  40. 40.
    Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46(3):325–415.PubMedGoogle Scholar
  41. 41.
    Nelson J et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3(2):110–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Eberl LP et al. Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer. 2000;86(2):182–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Asham E et al. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer. 2001;85(11):1759–63.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Takai D et al. Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis. Oncogene. 2001;20(51):7505–13.CrossRefPubMedGoogle Scholar
  45. 45.
    Kozminski KG et al. A motility in the eukaryotic flagellum unrelated to flagellar beating. Proc Natl Acad Sci U S A. 1993;90(12):5519–23.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Rosenbaum JL, Witman GB. Intraflagellar transport. Nat Rev Mol Cell Biol. 2002;3(11):813–25.CrossRefPubMedGoogle Scholar
  47. 47.
    Bhogaraju S et al. Molecular basis of tubulin transport within the cilium by IFT74 and IFT81. Science. 2013;341(6149):1009–12.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511.CrossRefPubMedGoogle Scholar
  49. 49.
    Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13(5):816–25.CrossRefPubMedGoogle Scholar
  50. 50.
    Gewirtz AT et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol. 2001;167(4):1882–5.CrossRefPubMedGoogle Scholar
  51. 51.
    Rhee SH et al. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci U S A. 2005;102(38):13610–5.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Kaisho T, Akira S. Pleiotropic function of Toll-like receptors. Microbes Infect. 2004;6(15):1388–94.CrossRefPubMedGoogle Scholar
  53. 53.
    Pimentel-Nunes P et al. Decreased Toll-interacting protein and peroxisome proliferator-activated receptor gamma are associated with increased expression of Toll-like receptors in colon carcinogenesis. J Clin Pathol. 2012;65(4):302–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Xu G et al. MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC Cancer. 2013;13:469.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    MacNeil AJ et al. MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer. Cancer Res. 2014;74(1):162–72.CrossRefPubMedGoogle Scholar
  56. 56.
    Jia M et al. Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified MAP2K3 as a senescence-promoting protein which is downregulated in human breast cancer. Proteomics Clin Appl. 2010;4(10–11):816–28.CrossRefPubMedGoogle Scholar
  57. 57.
    Galan-Moya EM et al. Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC. PLoS One. 2011;6(12), e28406.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Le Stunff C et al. Association analysis indicates that a variant GATA-binding site in the PIK3CB promoter is a Cis-acting expression quantitative trait locus for this gene and attenuates insulin resistance in obese children. Diabetes. 2008;57(2):494–502.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Sukhontip Klahan
    • 1
  • Chi-Cheng Huang
    • 2
    • 3
    • 4
  • Shu-Chen Chien
    • 1
    • 5
  • Mei-Shin Wu
    • 1
  • Henry Sung-Ching Wong
    • 5
  • Chien-Yu Huang
    • 6
  • Wei-Chiao Chang
    • 1
    • 5
  • Po-Li Wei
    • 1
    • 6
    • 7
    • 8
    • 9
    • 10
  1. 1.Department of Clinical Pharmacy, School of PharmacyTaipei Medical UniversityTaipeiTaiwan
  2. 2.Department of SurgeryCathay General HospitalNew Taipei CityTaiwan
  3. 3.School of MedicineFu-Jen Catholic UniversityNew Taipei CityTaiwan
  4. 4.School of MedicineTaipei Medical UniversityTaipei CityTaiwan
  5. 5.Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of PharmacyTaipei Medical UniversityTaipeiTaiwan
  6. 6.Division of General Surgery, Department of SurgeryDepartment of Neurosurgery Shuang Ho Hospital, Taipei Medical UniversityTaipeiTaiwan
  7. 7.Department of Surgery, College of MedicineTaipei Medical UniversityTaipeiTaiwan
  8. 8.Division of General Surgery, Department of SurgeryTaipei Medical University Hospital, Taipei Medical UniversityTaipeiTaiwan
  9. 9.Cancer CenterTaipei Medical University Hospital, Taipei Medical UniversityTaipeiTaiwan
  10. 10.Graduate Institute of Cancer Biology and Drug DiscoveryTaipei Medical UniversityTaipeiTaiwan

Personalised recommendations